A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.

A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.
复制标题

一种针对癌胎纤连蛋白的人单克隆抗体选择性地靶向体内慢性皮肤炎症。

DOI:
10.1038/sj.jid.5700653
复制
发表时间:
2007
期刊:
The Journal of investigative dermatology
影响因子:
--
通讯作者:
Neri,Dario
Neri,Dario
中科院分区:
--
文献类型:
--
作者:
Trachsel,Eveline;Kaspar,Manuela;Bootz,Frank;Detmar,Michael;Neri,Dario

文献摘要

参考文献

被引文献

相似文献

基于抗体的生物活性剂靶向递送至血管生成部位是用于癌症治疗的有吸引力的治疗策略,但对于慢性炎性疾病在很大程度上未被探索。在这篇文章中,我们表明,额外的结构域B(EDB)结构域的纤连蛋白,血管生成的标志物,表达在银屑病病变,抗EDB人抗体L19可以选择性地定位到慢性炎症皮肤在体内。基于L19的细胞因子IL 10和IL 12的递送没有改善或恶化慢性皮肤炎症小鼠模型中的炎症,所述慢性皮肤炎症小鼠模型在角蛋白-14启动子的控制下过表达血管内皮生长因子。相比之下,促炎细胞因子IL 2或光敏剂Sn(IV)二氢卟酚e6的基于L19的靶向递送导致发炎皮肤的肿胀和发红增加。这些结果表明,特异性抗体的修改细胞外基质的成分可以选择性地积累在慢性炎症部位在体内。这一观察结果现在刺激了对生物活性分子的研究,这些生物活性分子可以与抗体融合,并且由于它们在银屑病病变和其他炎症部位的优先积累而可以赋予治疗益处。
The antibody-based targeted delivery of bioactive agents to sites of angiogenesis is an attractive therapeutic strategy for cancer treatment, but is largely unexplored for chronic inflammatory diseases. In this article, we show that the extra domain B (EDB) domain of fibronectin, a marker of angiogenesis, is expressed in psoriatic lesions, and that the anti-EDB human antibody L19 can selectively localize to chronically inflamed skinin vivo. The L19-based delivery of the cytokines IL10 and IL12 did not improve or worsen inflammation in a mouse model of chronic skin inflammation, which overexpressed vascular endothelial growth factor under the control of the keratin-14 promoter. By contrast, the L19-based targeted delivery of the proinflammatory cytokine IL2 or of the photosensitizer Sn(IV) chlorin e6 resulted in an increased swelling and reddening of inflamed skin. These results indicate that antibodies specific to components of the modified extracellular matrix can selectively accumulate at chronically inflamed sitesin vivo. This observation now stimulates the search for bioactive molecules which can be fused to antibodies and which may confer a therapeutic benefit as a result of their preferential accumulation in psoriatic lesions and other sites of inflammation.
用于血管生成抑制、血管靶向和内皮细胞转胞吞作用的抗体。
DOI: --
发表时间: 2006
影响因子: 16.1
作者:
E. Trachsel;D. Neri
通讯作者: D. Neri
DOI: 10.1016/s0002-9440(10)64446-x
发表时间: 2002-11-01
影响因子: 6
作者:
Castellani, P;Borsi, L;Zardi, L
通讯作者: Zardi, L
银屑病的初始事件:定量评估*
DOI: 10.1111/j.1365-2133.1973.tb02986.x
发表时间: 1973
影响因子: 10.3
作者:
E. Christophers;R. Parzefall;O. Braun
通讯作者: O. Braun
DOI: 10.1002/j.1460-2075.1987.tb02509.x
发表时间: 1987-08-01
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
ZARDI, L;CARNEMOLLA, B;BARALLE, FE
通讯作者: BARALLE, FE
DOI: 10.1172/jci22147
发表时间: 2004-06
期刊: The Journal of clinical investigation
影响因子: --
作者:
B. Nickoloff;F. Nestle
通讯作者: B. Nickoloff;F. Nestle